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Abstract
High-grade serous ovarian/tubal cancer commonly spreads via the peritoneal and lym-
phatic routes. This chapter discusses the anatomical lymphatic drainage of the ovary and 
tube with reference to spread from different epithelial ovarian cancer types. The role of 
lymph node surgery in apparent early stage curative disease will be discussed with refer-
ence to staging and directing the need for adjuvant chemotherapy. In advanced disease, 
the role of lymph node sampling versus systematic dissection surgery as part of cyto-
reduction is assessed. The result of two randomised controlled trials (RCTs) published 
on the subject will be analysed along with the ongoing Lymphadenectomy in Ovarian 
Neoplasia (LION) study. The chapter adopts an evidence-based approach to the role of 
lymph node surgery in women with epithelial ovarian/tubal cancer.
Keywords: epithelial ovarian/tubal cancer, high-grade serous, para aortic lymph node, 
pelvic lymph node, systematic dissection sampling, FIGO staging
1. Introduction
The modern of management of  women with ovarian involves complete surgical cyto-
reduction of all visible disease [1]. It is therefore important to understand that approxi-
mately 70% of the women will also have lymphatic spread. Even in disease, apparently 
confined to one or both ovaries, there is evidence of nodal metastatic spread in up to 24% 
of women [2].
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the t rms of the Crea ive
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2. The lymphatic drainage of the ovaries
An understanding of the lymphatic drainage of the ovary and fallopian tube is important in 
the management of women with ovarian cancer. There are three main lymphatic pathways. 
The principal pathway is along the ovarian vessels through the infundibulopelvic ligament 
to the para aortic and para caval nodes surrounding the aorta and inferior vena cava (IVC). 
The second pathway occurs through the broad ligaments into the pelvic nodal region. Of note, 
spread to contralateral pelvic nodes in women with a unilateral cancer is reported in up to 30% 
of women [3]. Therefore, a bilateral pelvic node dissection (PND) is recommended even with 
unilateral apparent stage 1 tumours.
A third lesser route is through the uterine round ligament to the inguinal nodes. In addition, 
women with disease involving the rectum or sigmoid colon may have tumour spread to the 
mesocolic lymph nodes within the sigmoid mesentery.
3. Is histopathological type important?
Over the last decade, the understanding of the pathogenesis of epithelial ovarian cancer has 
changed. The most common histopathological subtype, high-grade serous cancer (approxi-
mately 70–80% of cases) appears to arise in the distal fallopian tube [4]. Most of these women 
present with disease spread to the transperitoneal surfaces and to the lymph system. The major-
ity of this chapter will be concerned with the role of lymphadenectomy in this group of women.
Less common types of ovarian cancer include endometrioid, clear cell, low grade serous 
and mucinous  tumours. These appear to have separate aetiologies with a different risk of 
lymphatic spread. The risk of nodal metastases appears to be lower in endometrioid and 
mucinous cancers. For example, a meta-analysis of 278 women with apparent early mucinous 
cancer of the ovary who underwent a full pelvic and para aortic nodal dissection reported an 
incidence of involved nodes of only 1.2% [5]. Most authors no longer recommend a lymphad-
enectomy in early mucinous cancers.
4. What are the methods of surgical assessment?
A definition of a pelvic node dissection (PND) is widely accepted in the gynaecological oncol-
ogy literature [6]. PND includes bilateral removal of nodal tissue from the distal one-half 
of each common iliac artery, the anterior and medial aspect of the external iliac artery and 
vein to the level of the deep circumflex artery, and obturator fat pad anterior to the obturator 
nerve. The medial aspect of the dissection is the hypogastric artery. Enlarged nodes below 
the obturator nerve should also be removed. The obturator nerve should be identified and 
guarded prior to any sharp dissection. The nodes should be swept away from the nerve with 
careful attention paid to the area below the nerve to avoid damage to the numerous vessels 
present in this area. The ideal scenario is to remove the node in a single nodal unit to reduce 
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the risk of nodal fracture leading to possible tumour dissemination and port site metastases. 
A PND may be performed either as an open procedure or as part of a laparoscopic procedure. 
Laparoscopic surgery lends itself to PND due to the increased magnification and illumination 
of the surgical field and dissected nodes can be removed through an 11/12 mm suprapubic 
port or removed via the vagina if a hysterectomy is performed.
Para aortic assessment/dissection has in contrast to pelvic nodes not been well quantified. 
Pomel et al. [7] have published a proposed classification of para aortic node assessment which 
ranges from radiological assessment and palpation to a full systematic dissection of all nodal 
tissue including the dorsal surfaces of the vessel (Table 1).
Open para aortic dissection (type A1 to B1) requires a generous midline abdominal incision 
to the xiphisternum and a self-retaining retractor to allow access to the great vessels. The 
right side of the colon and small bowel are mobilised by incising the peritoneum at the level 
of the right common iliac artery extending medially and caudally to the fourth part of the 
duodenum and then incising the peritoneum along the right paracolic gutter to the hepatic 
flexure. This allows the surgeon to perform called ‘Kocher manoeuvre’ mobilising the bowel 
off both the right renal fascia and ureter and to be retracted out of the abdomen. Following 
this, the surgeon should identify the left ureter lying medially underneath the inferior mesen-
teric vein. The node dissection should not start until all the important anatomical structures 
have been identified including the inferior mesenteric artery (IMA).
Laparoscopic PA node dissection is well described in the literature and can be performed either 
via the conventional transperitoneal route or via an extra peritoneal route. Both routes require 
a high degree of laparoscopic training and is considered unlikely to replicate a systematic node 
dissection (Pommel type A) but rather an extensive node sampling (Pommel type B1–2).
Type
A Systematic para aortic node dissection
A1 Complete (includes infrarenal and suprarenal up to coeliac trunk to midpoint of common iliac vessels)
A2 Infrarenal (as above, but does not include suprarenal dissection)
A3 Infra inferior mesenteric artery (IMA) (as above but does not include dissection above IMA)
B Para aortic sampling
B1 Extensive (incudes para aortic areas, but does not allow full visualisation of structures—adventicia of 
vessels. Renal vessels, anterior common vertebral ligament, psoas muscle and sacrum
B2 Minimal (includes limited para aortic areas, and does not allow visualisation of structures above)
C Non-excisional assessment
C1 Palpation (direct) following full exposure of PA area
C2 Palpation (indirect), transperitoneal without any exposure
C3 Radiological assessment by PET/CT or MRI
Table 1. Proposed classification of para aortic node assessment (Pomel et al. [7]).
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5. What is the role of lymphadenectomy in apparent early stage 
ovarian cancer?
A number of women will undergo surgery for an apparently benign ovarian cyst. Postoper-
atively, those women with confirmed malignancy can be offered staging including lymphad-
enectomy. Approximately, 30% of women with ovarian cancers apparently confined to the 
ovaries will be upstaged following further surgery including a pelvic/para aortic node dissec-
tion/sampling (Pommel type B1) with a gynaecological oncologist [8].
It is important to understand that lymph node status is not the only factor that determines the 
need for adjuvant chemotherapy. Many centres offer chemotherapy to women with stage Ic 
or above cancers, high-grade lesions and all clear cell cancers of the ovary [9].
However, node status is important for a number of reasons: it may influence whether or not 
chemotherapy is given, the number of cycles or types of chemotherapy and it may result in 
complete cytoreduction of the cancer. Node status also partially determines the true FIGO 
stage and prognosis.
The ACTION trial was a randomised controlled trial (RCT) of 448 women with stage IA, IB 
grades 2–3, all IC, IIA and all clear cell cancer stage I–IIA and compared the administration 
of adjuvant chemotherapy with a control arm. The main finding showed overall survival was 
significantly better with the administration of chemotherapy. A subset analysis revealed that 
stage I patients with complete surgical staging did not benefit from chemotherapy contrast 
to patients that underwent incomplete staging [10]. Long-term follow-up of this study has 
confirmed these results [11]. It has been surmised that patients that have not being staged 
harbour more advanced disease, and therefore have a poorer prognosis and chemotherapy 
does not compensate for incomplete staging.
In older women with complex masses or those felt to have a high risk of cancer, an intraopera-
tive frozen section histopathological analysis may be performed. A study from the Gateshead 
Gynaecological Oncology Centre reported a with a sensitivity of 92%, specificity of 88%, posi-
tive predictive value of 82% and negative predictive value of 95% for frozen section analysis 
[12]. This is equally important in determining which women should not be exposed to unnec-
essary surgery such as a para aortic node dissection.
Laparoscopic staging is possible, though requires a high degree of specialist training. Several 
centres have reported on full laparoscopic staging and have found it feasible [13, 14]. Chi 
et al. performed a case control study comparing staging via laparoscopy or laparotomy in 80 
women [13]. They found no difference in specimen sizes and lymph nodal counts. The lapa-
roscopic group had levels of reduced blood loss and a reduced hospital stay. A laparoscopic 
nodal dissection/sampling should include both the pelvic and para aortic basins to the level of 
the renal vessels. A case series by Nezhat et al. [15] concluded that laparoscopic staging when 
performed by a gynaecological oncologist did not compromise survival.
Robotically assisted laparoscopic surgery is an evolution of minimal access surgery rather 
than a revolution. Perceived benefits include three-dimensional vision, control of the laparo-
scope by the operating surgeon, more precise instrument movement and a shortened  learning 
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curve. Perhaps, the biggest advantage is the use of instruments that fully articulate at the 
end in the manner of a human wrist allowing fine delicate movements. This is particularly 
important in the obese patient, where the increased thickness of the anterior abdominal wall 
produces an increased torque effect leading to decrease manoeuvrability of standard laparo-
scopic instruments. Robotic platforms have been used in staging apparent ovarian cancer and 
appear comparable to laparoscopic surgery [16–19].
Maggioni et al. [20] reported a randomised controlled trial of 268 women with apparent stage 
1 or 2 ovarian epithelial cancer. The women were randomised to either a random sampling 
of pelvic and PA nodal basin or systematic dissection (pommel type A) of the same areas. 
Positive nodes were found in 9% of the control group and in 22% of the SLD group. No sig-
nificant difference was recorded in 5 years year overall survival (84.2 vs. 81.3%) or progression 
free survival (PFS) (78.3 vs. 71.3). The SLD group had a significantly longer operating time, 
blood loss and blood transfusion.
In view of the results of this study, SLD should not be offered over more limited dissection/
sampling (pommel B) in women with apparent early ovarian cancer.
6. What is the role of lymphadenectomy in advanced ovarian cancer?
The goal of surgery in advanced ovarian cancer is to remove all visible disease including a 
removal of all enlarged lymph nodes. This requires intraoperative assessment of the bilateral 
pelvic nodes and the para aortic region (pommel type C1–B1).
Given that the nodal basin is considered by some to be relatively chemotherapy insensitive, 
this to the question whether removal of all involved microscopically and macroscopically 
involved nodes has a therapeutic benefit.
Panici et al. [21] reported a randomised controlled trial of 268 women with apparent stage 
IIIB, IIIC/IV cancer. The women were randomised to either resection bulky of pelvic and PA 
nodes or systematic dissection of the same areas. Positive nodes were found in 42% of the con-
trol group and in 42% of the SLD group. No significant difference was recorded in 5 years year 
overall survival (47 vs. 48.4%). A significant 7-month extension in progression free survival 
(PFS) was demonstrated (29.4 vs. 22.4 months). The SLD group had a significantly longer 
operating time, blood loss and blood transfusion. Subsequently, the authors have suggested 
that the study may be underpowered to detect an overall survival difference.
7. Common complications
7.1. Vascular injury
Working in close proximity to the large blood vessels poses a risk of major haemorrhage. 
Reducing this risk involves an appropriate surgical incision with a good operative exposure 
involving dissection/identification of anatomical structures. This allows easier identification 
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of vascular anomalies and reduces the risk of collateral damage to structures such as the 
kidney and ureter. Initial management includes pressure to the area and appropriate com-
munication with the rest of the team including the anaesthetist. Small vascular injuries may 
be oversewn using a vascular needle and small monofilament suture, ideally avoiding con-
stricting the vessel’s diameter. Larger defects require the vascular clamp and the expertise of 
a vascular surgeon.
7.2. Lymphocyst formation
The incidence of lymphocyst after the para aortic/pelvic dissection maybe as high as 43% 
[22]. The vast majority of these will resolve spontaneously and do not require any interven-
tion. Occasionally, a larger lymphocyst may require aspiration typically by interventional 
radiological drainage. Occasionally, chylous ascites develop in association with an aortic 
node dissection especially at the level of the renal vessels. This illustrates the importance clip-
ping large lymphatic channels especially in this region. Management of how chylous ascites 
includes the low-fat diet, the administration of somatosatin and occasionally total parenteral 
nutrition.
7.3. Other complications
Other complications associated with lymph node dissection include postoperative ileus, dam-
age to the duodenum, damage to relevant nerves and long-term lymphoedema.
8. Ongoing research into lymphadenectomy
8.1. Early stage ovarian/tubal cancer
Serous tubal intraepithelial carcinoma (STIC) is now considered the precursor lesion for 
high-grade serous cancer [4]. STIC may be an incidental finding in women undergoing a 
salpingectomy for benign reasons and the incidence is expected to rise in women undergoing 
risk reducing surgery for ovarian/tubal cancer. The management of women with STIC as an 
incidental finding it is unclear. It is apparent, the percentage of these women will have dis-
seminated spread of high-grade serious cancer. Based on small series, authors have suggested 
comprehensive surgical staging including lymphadenectomy [23, 24]. This is relatively a new 
condition with larger case series publication expected over the next few years.
8.2. Advanced stage cancer
Following the Panici study reporting a significant difference in PFS, the role of a full system-
atic node dissection is the subject of two randomised controlled trials, the Lymphadenectomy 
in Ovarian Neoplasia (LION) and CURACO trials [21].
The Lymphadenectomy in Ovarian Neoplasia (LION) study is an AGO randomised con-
trolled trial including women with FIGO stage IIB–IV ovarian epithelial cancer and complete 
Ovarian Cancer - From Pathogenesis to Treatment266
macroscopic resection of all disease. Around 640 women were randomised to either a full 
systematic lymph node (SLN) or no lymph node dissection and the study results are due in 
late 2017. The primary end point is overall survival (OS) and secondary endpoints include 
progression free survival (PFS) and quality of life (QOL).
The French CURACO trial is a randomised controlled trial including women with stage 
III–IV epithelial ovarian cancer with complete macroscopic resection. The women are being 
randomised to SLN versus no node dissection. The primary end point is progression free 
survival.
9. Conclusion
Spread to the lymphatic system is common in epithelial ovarian cancer is common and is 
an early event. Para aortic and bilateral pelvic node dissection sampling (Pommel type B1) 
should be included in surgical staging to determine chemotherapy use and to improve prog-
nosis in ovarian cancer apparently confined to the ovary based on the results of the ACTION 
trial.
In women with advanced ovarian, the retroperitoneal lymph nodes should be assessed and 
bulky lymph nodes removed in an attempt to achieve complete cytoreduction. Systematic 
lymph node (SLN) of the para aortic nodes should not be routinely performed pending the 
results of the LION and CURACO studies.
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